

**Baxter International Inc.**  
**Key Product Line Sales -- US/International**  
**Period Ended September 30, 2006**  
**(unaudited)**  
**(\$ in millions)**

	Q3 2006			Q3 2005 <sup>1</sup>			% Growth		
	US	International	Total	US	International	Total	US	International	Total
<b>BioScience</b>									
Recombinants	\$182	\$251	\$433	\$170	\$222	\$392	7%	13%	10%
Plasma Proteins <sup>2</sup>	87	127	214	61	115	176	43%	10%	22%
Antibody Therapy	146	50	196	83	40	123	76%	25%	59%
BioSurgery <sup>3</sup>	40	32	72	35	28	63	14%	14%	14%
Transfusion Therapies	60	61	121	66	68	134	(9%)	(10%)	(10%)
Other <sup>4</sup>	13	39	52	34	28	62	(62%)	39%	(16%)
<b>Total BioScience</b>	<b>\$528</b>	<b>\$560</b>	<b>\$1,088</b>	<b>\$449</b>	<b>\$501</b>	<b>\$950</b>	<b>18%</b>	<b>12%</b>	<b>15%</b>
<b>Medication Delivery</b>									
IV Therapies <sup>5</sup>	\$103	\$214	\$317	\$101	\$200	\$301	2%	7%	5%
Drug Delivery	128	77	205	120	72	192	7%	7%	7%
Infusion Systems	118	79	197	118	66	184	-%	20%	7%
Anesthesia and Injectable Drugs	135	86	221	184	75	259	(27%)	15%	(15%)
Other <sup>6</sup>	5	5	10	8	13	21	(38%)	(62%)	(52%)
<b>Total Medication Delivery</b>	<b>\$489</b>	<b>\$461</b>	<b>\$950</b>	<b>\$531</b>	<b>\$426</b>	<b>\$957</b>	<b>(8%)</b>	<b>8%</b>	<b>(1%)</b>
<b>Renal</b>									
PD Therapy	\$67	\$342	\$409	\$66	\$320	\$386	2%	7%	6%
HD Therapy	28	82	110	30	75	105	(7%)	9%	5%
<b>Total Renal <sup>7</sup></b>	<b>\$95</b>	<b>\$424</b>	<b>\$519</b>	<b>\$96</b>	<b>\$395</b>	<b>\$491</b>	<b>(1%)</b>	<b>7%</b>	<b>6%</b>
<b>TOTAL BAXTER</b>	<b>\$1,112</b>	<b>\$1,445</b>	<b>\$2,557</b>	<b>\$1,076</b>	<b>\$1,322</b>	<b>\$2,398</b>	<b>3%</b>	<b>9%</b>	<b>7%</b>

<sup>1</sup> Prior year sales data has been reclassified to reflect the changes that are described in notes 2, 3, 4 and 7 below.

<sup>2</sup> Includes plasma-derived hemophilia (FVII, FVIII, FIX and FEIBA), albumin, and certain other plasma-based products. Sales of Tisseel, sales of plasma to third parties, and contract manufacturing revenues were previously reported in Plasma Proteins, and are now reported in other product lines, as detailed below.

<sup>3</sup> Includes sales of Tisseel and FloSeal/CoSeal, which were previously reported in Plasma Proteins and Other, respectively.

<sup>4</sup> Principally includes vaccines and sales of plasma to third parties. The sales of plasma to third parties were previously reported in Plasma Proteins. The prior year sales include contract manufacturing revenues.

<sup>5</sup> Principally includes intravenous solutions and nutritional products.

<sup>6</sup> Principally includes other hospital-distributed products.

<sup>7</sup> Sales of pharmaceutical and certain other products, which were previously reported in Other, are now reported in PD Therapy.